What are the initial lab tests and management recommendations for a newly diagnosed hypertensive patient?

Initial Laboratory Workup for Newly Diagnosed Hypertension

All newly diagnosed hypertensive patients require a standardized set of routine laboratory tests to assess cardiovascular risk, detect target organ damage, and screen for secondary causes of hypertension. 1, 2

Mandatory Routine Laboratory Tests

The following tests should be obtained in all patients with newly diagnosed hypertension:

Renal Function Assessment

• Serum creatinine with calculated eGFR (using race-free CKD-EPI equation) 1
• Urine albumin-to-creatinine ratio (ACR) 1
• Urinalysis with microscopy (assess for red cells, leukocytes, casts) 3, 4
• If moderate-to-severe CKD is identified (eGFR <60 mL/min/1.73 m² or albuminuria ≥30 mg/g), repeat these measurements at least annually 1

Metabolic and Electrolyte Panel

• Serum electrolytes (sodium and potassium) 3, 5
• Fasting blood glucose 3, 6
• HbA1c 6
• Recent evidence shows 8.4% of newly diagnosed hypertensives have undiagnosed diabetes (glucose >125 mg/dL) and 7.5% have HbA1c >6.5% 6

Lipid Assessment

• Complete lipid panel (total cholesterol, LDL, HDL, triglycerides) 3, 6
• Over 54% of newly diagnosed hypertensives have LDL >100 mg/dL, requiring concurrent cardiovascular risk management 6

Cardiac Evaluation

• 12-lead electrocardiogram (ECG) in all patients 1, 5
• Assess for left ventricular hypertrophy, atrial fibrillation, and ischemic changes 1
• Repeat ECG whenever patients present with irregular pulse or cardiac symptoms 1

Additional Routine Tests

• Complete blood count (CBC) with hemoglobin and platelet count 3, 4
• Liver function tests (LDH, haptoglobin if indicated) 4

Cardiovascular Risk Stratification

After obtaining baseline labs, perform formal cardiovascular risk assessment:

• Use SCORE2 for ages 40-69 years or SCORE2-OP for ages ≥70 years to calculate 10-year CVD risk 1
• Patients with ≥10% CVD risk, or those with diabetes, moderate-to-severe CKD, or established CVD are automatically considered high-risk and warrant immediate pharmacological treatment even with stage 1 hypertension 1, 5

Optional Tests Based on Clinical Indication

Consider these additional tests when clinically indicated to assess hypertension-mediated organ damage (HMOD):

Advanced Cardiac Assessment

• Echocardiography is recommended if ECG is abnormal, cardiac murmurs are detected, or cardiac symptoms are present 1
• May be considered for all newly diagnosed hypertensives if resources allow, as it detects subclinical left ventricular dysfunction and hypertrophy that predict CVD events 1
• High-sensitivity cardiac troponin and NT-proBNP for assessing HMOD 1

Vascular Assessment

• Coronary artery calcium (CAC) scoring by cardiac CT may be considered when it would change management 1
• Carotid-femoral or brachial-ankle pulse wave velocity (PWV) for arterial stiffness assessment 1
• Ankle-brachial index if peripheral arterial disease is suspected 1

Renal Imaging

• Renal ultrasound with Doppler should be considered in patients with CKD to assess kidney structure and exclude renovascular hypertension 1
• CT or MRI renal angiography are alternatives for suspected renovascular disease 1

Ophthalmologic Evaluation

• Fundoscopy is recommended if BP >180/110 mmHg to evaluate for hypertensive emergency/malignant hypertension (hemorrhages, exudates, papilledema) 1, 4
• Also recommended in hypertensive patients with diabetes 1

Screening for Secondary Hypertension

Screen for secondary causes when suggestive clinical features are present:

Clinical Red Flags Requiring Further Investigation

• Age <30 years or rapid onset/progression of hypertension 3
• Resistant hypertension (uncontrolled on 3+ medications including a diuretic) 1
• Hypokalemia (consider primary aldosteronism) 1
• Abdominal bruit (renovascular hypertension) 3
• Features of Cushing syndrome or pheochromocytoma 3

Specific Secondary Hypertension Tests (When Indicated)

• Plasma or urinary fractionated metanephrines for suspected pheochromocytoma 4
• Plasma aldosterone and renin for primary aldosteronism screening 1
• Renal artery duplex Doppler or angiography for renovascular disease 1, 4

Critical Timing Considerations

Reassess electrolytes and renal function 2-4 weeks after initiating RAS inhibitor or diuretic therapy to detect hyperkalemia or acute kidney injury 5

Clinical Impact of Complete Workup

A complete baseline laboratory assessment significantly improves blood pressure control: patients receiving complete workup achieve better systolic BP at 12 months (129.9 mmHg) compared to partial workup (142.8 mmHg, P=0.003) 6. The complete workup also unmasks critical comorbidities including CKD (7.5% with eGFR <60), diabetes (8.4%), and dyslipidemia (54.2%) that require concurrent management 6.

Common Pitfalls to Avoid

• Do not skip urine ACR measurement—it's essential for detecting early kidney damage and is required for all hypertensive patients 1
• Do not use race-based eGFR equations—use the race-free CKD-EPI equation 1
• Do not order routine genetic testing—it is not recommended for typical hypertensive patients 1
• Do not delay treatment while awaiting specialty testing—initiate therapy based on routine labs and BP category, then pursue additional workup as indicated 5